ArticleJournal of Cancer2015
Promoter Hypermethylation in White Blood Cell DNA and Breast Cancer Risk.
Article in Journal of Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Pooled it
- Blood DNA methylation and breast cancer risk: a meta-analysis of four prospective cohort studies.Breast cancer research : BCR · 2019Pooled it
- Promoter Methylation Status of the Retinoic Acid Receptor-Beta 2 Gene in Breast Cancer Patients: A Case Control Study and Systematic Review.Breast care (Basel, Switzerland) · 2019Pooled it
- Blood-based DNA methylation as biomarker for breast cancer: a systematic review.Clinical epigenetics · 2016Pooled it
- ConstitutionalInternational journal of molecular sciences · 2024Article
- Increased CpG methylation at the CDH1 locus in inflamed ileal mucosa of patients with Crohn disease.Clinical epigenetics · 2024Article
- Evaluation of BRCA1 Gene Promoter Methylation Status in Sporadic Breast Cancer Patients in Southwest of Iran.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Methylation of promoter region of BRCA1 gene versus pathogenic variants of gene: risk factor or clinical marker of breast cancer.Breast cancer research and treatment · 2022Article
- Young Breast Cancer: Novel Gene Methylation in WBC.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Methylated biomarkers for breast cancer identified through public database analysis and plasma target capture sequencing.Annals of translational medicine · 2021Article
- Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer.British journal of cancer · 2020Review
- DDT exposure during pregnancy and DNA methylation alterations in female offspring in the Child Health and Development Study.Reproductive toxicology (Elmsford, N.Y.) · 2020Article
- Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters.Clinical epigenetics · 2018Article
- Evaluation of Promoter Methylation of RASSF1A and ATM in Peripheral Blood of Breast Cancer Patients and Healthy Control Individuals.International journal of molecular sciences · 2018Article
- Integrative analysis of gene expression and methylation data for breast cancer cell lines.BioData mining · 2018Article
- Aberrant methylation ofJournal of Cancer · 2018Article
- Breast cancer family history and allele-specific DNA methylation in the legacy girls study.Epigenetics · 2018Article
- Experimental factors affecting the robustness of DNA methylation analysis.Scientific reports · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
The role of gene-specific methylation in white blood cells (WBC) as a marker of breast cancer risk is currently unclear. We determined whether promoter hypermethylation in blood DNA of candidate tumor suppressor genes frequently methylated in breast tumors can be used as a surrogate biomarker for breast cancer risk. Promoter methylation of BRCA1, CDH1 and RARβ was analyzed in WBC DNA from a population-based sample of 1,021 breast cancer patients and 1,036 controls by the MethyLight assay. Gene-specific promoter methylation in the DNA of 569 tumor tissue samples was also analyzed to determine the correlation of methylation levels with blood from the same individual. Hypermethylation of BRCA1 (OR: 1.31; 95% CI: 0.98-1.75) in WBC was associated with an increased risk of breast cancer when positive methylation was defined as ≥0.1% methylated. There was lack of concordance between tumor tissue and paired WBC DNA methylation. These results provide limited support that hypermethylation of BRCA1 in WBC DNA may be useful for determination of breast cancer risk. Additional studies with larger numbers of genes are needed to fully understand the relationship between WBC methylation and breast cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.